Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 4, 2014

Primary Completion Date

December 16, 2019

Study Completion Date

June 15, 2020

Conditions
Hodgkin's LymphomaNon-Hodgkin's Lymphoma
Interventions
DRUG

Bendamustine

Days - 24 and Day - 23 followed by a short break of 10 - 14 days.

DRUG

Carmustine

300 mg/m2 on Day -6

DRUG

Etoposide

100 mg/m2 on days -5 to -2

DRUG

Melphalan

140mg/m2 on Day -1

DRUG

Cytarabine

200 mg/m2 on days -5 to -2

DRUG

Alemtuzumab

20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors

BIOLOGICAL

Autologous Stem Cell Transplantation

BIOLOGICAL

Allogeneic Stem Cell Transplantation

DRUG

Rituximab

Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant

Trial Locations (1)

10065

Weill Cornell Medical College, New York

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT02059239 - Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | Biotech Hunter | Biotech Hunter